Best Practices: Drug Safety in the Life Science Industry — A Market Landscape
|Author:||Alan S. Louie, Ph.D.|
|Document Type||Best Practices|
|Number of Pages||13|
|Number of Figures||6|
This IDC Health Insights report lays out the changing landscape for drug safety in the life science industry with a focus on the key processes, commercial tools, and available external service resources that are currently used to help organizations ensure and maintain full global regulatory compliance. As a core process in an industry undergoing transformation, drug safety is an area that is also being pressed for improved cost efficiency while concurrently facing an increasingly complex regulatory environment as companies expand globally.
"While global intolerance for drugs that are less than perfect in their safety profiles remains at an all-time high, life science companies still need to bring new drugs to market to survive. Faster and better use and exploitation of drug safety data across organizations will be key to working smarter and staying ahead as companies move into a new era in the life sciences," says Alan S. Louie, research director, IDC Health Insights.
Our records show that you do not have access to this document.